Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
108
self-reported 51–200 band
Founded
2004
22 years
Legal entities
1
ABR
Office countries
3
3 addresses
Funding rounds
9
Post IPO debt · Oct 2024 · US$ 50.0M
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
MESOBLAST LIMITED
ABN68109431870
Legal entities
Show as table · Mesoblast Limited: 1 registry entity
| MESOBLAST LIMITED | ABN 68109431870 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs.
The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are:
- RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD)
- Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection
- REVASCOR® for advanced chronic heart failure, and
- MPC-06-ID for chronic low back pain due to degenerative disc disease.
The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians.
Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.
Specialties
All 9 specialties
- Cell-based therapies
- cellular medicines
- Mesenchymal Lineage Adult Stem Cells
- regenerative medicine
- COVID-19
- Chronic Heart Failure
- Graft Versus Host Disease
- Chronic Low Back Pain
- Rheumatoid Arthritis
Locations
3
Countries with an office address3 addresses on record
Country footprint
Show as table · Offices in 3 countries
| Countries | 3 |
|---|---|
| Primary country | AU |
All codes: AU SG US
Addresses
- AULevel 38, 55 Collins St; Melbourne, VIC 3000Primary
- US505 Fifth Avenue; Third Floor; New York, New York 10017
- SG20 Biopolis Way #05-01 Centros; Biopreneur 3; Singapore, Singapore 138668
Grid intelligence Members
Funding
Last round · 29 October 2024US$ 50.0MPost IPO debt
Rounds9
Round typePost IPO debt · non-equity funding
Amount (USD)50,000,000
Stage rank6
Investors named1
Since last round1 yr 2 mo
Funding
Show as table · 9 funding rounds
| Rounds | 9 |
|---|---|
| Axis | 2004 to 2026 |
| Post IPO debt · 29 Oct 2024 | US$ 50.0M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under Mesoblast Limited?
One Victoria entity on the ABR. MESOBLAST LIMITED (ABN 68 109 431 870), high confidence.
How many people work at Mesoblast Limited?
The record holds 108 counted staff profiles at January 2026, inside the self-reported 51–200 band.
Where does Mesoblast Limited have offices?
Three addresses on record across 3 countries. Primary: Level 38, 55 Collins St, Melbourne, VIC 3000.
Has Mesoblast Limited raised funding?
Nine rounds. Latest 29 October 2024: post IPO debt, US$50,000,000.
What does Mesoblast Limited list as its specialties?
Nine tags on the brand's own list, among them covid-19 and regenerative medicine.
Which companies are listed alongside Mesoblast Limited?
24 profiles list Mesoblast Limited as a peer — 95th percentile in Biotechnology Research. It lists ten peers of its own. Orthocell Ltd and CLINUVEL PHARMACEUTICALS LTD list it back.